Tagged with J

Taiwan Wang Yu Pei, general manager of Nang Kuang Pharmaceutical, Taiwan’s indisputable market leader for injectable products, provides insights into the global ambitions of the company as Nang Kuang is about to bring its first injectable into the US market and is also looking for Europe-based partners to distribute its high-quality…

Switzerland The global leader in the specialized niche of micronization services, Jetpharma is set for continued steady growth driven by the continued development of extremely dangerous-to-handle highly potent active ingredients. To begin, could you please introduce Jetpharma and the field of micronization to our readers? “Jetpharma has over 40 years of…

Taiwan Yung Fa Chen, ScinoPharm’s President and CEO, documents his strategy to drive the Taiwan-based global success story to new heights, having established itself as an indisputable leader in the API field, providing its international partners with complex, difficult-to-make products. Yung Fa Chen notably explains how he wants to further leverage…

Taiwan JCP is home to over five decades of generic medication production and is a cornerstone household brand for numerous products in Taiwan’s domestic market, most notably with CNS medications. The company’s chairman and CEO, PH Huang details how they have gone about utilizing their post-IPO funds to enhance the company’s…

Greece Efthymios (Makis) Papataxiarchis, Managing Director of Janssen Pharmaceutical companies, Johnson & Johnson Greece, Malta & Cyprus, on spearheading a large multinational company through the largest economic crisis in Europe. He speaks about Janssen’s portfolio in Greece, how to mitigate challenges in market access, as well as igniting a solutions-driven dialogue…

Greece  Astellas Greece & Cyprus MD, Harry Nardis, emphasizes the importance of integrity, compliance and innovation to the Astellas business model, key priorities, navigating the Greek pharmaceutical landscape while maintaining a high-quality reputation, and retaining the company’s vision of being at the forefront of healthcare change. Having assumed the leadership position…

Greece “There is nothing so stable as change” says chairman of the medical devices and diagnostics committee for the American Chamber of Commerce and GM for J&J Medical Hellas, Theodore Liakopoulos. Having spearheaded the affiliate through the economic crisis, Liakopoulos speaks candidly about his strategic priorities, the importance of staying agile to…

Ireland Philip Martin, founder and CEO of Cora Systems in Ireland, explains why his company is ideally positioned to help the pharmaceutical industry increase efficiency and save costs through their agile, flexible and intuitive project management software solutions. “Along with tech improvements, incredible new complexity in how the industry operates has…

Ireland Jim Curley, the CEO of Jones Engineering Group, details the company’s more than 125-year history in Ireland and in more recent times across the UK, mainland Europe and the Middle East. He gives an insight into how they have maintained their leadership role in the engineering contracting industry particularly in…

Singapore The Asia-Pacific region is a vast geographic area, home to almost half of the world’s population and numerous emerging and developed markets with great investment potential for healthcare and life sciences companies. However, the degree of diversity within Asia-Pacific creates formidable challenges for MNCs operating in the region. “APAC is…

Singapore With healthcare demand rapidly increasing in Asia Pacific and worldwide, the entire healthcare sector is sure to undergo a dramatic revolution. J&J Medical’s Chairman for Asia Pacific discusses his priorities for the company, and for the wider life science industry in his capacity as Chairman of APACMed. You have served…

London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…